A detailed history of Ikarian Capital, LLC transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Ikarian Capital, LLC holds 22,800 shares of FULC stock, worth $106,704. This represents 0.01% of its overall portfolio holdings.

Number of Shares
22,800
Holding current value
$106,704
% of portfolio
0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.18 - $9.74 $238,500 - $730,500
75,000 New
75,000 $267,000
Q3 2021

Nov 15, 2021

SELL
$7.28 - $30.97 $1.18 Million - $5.04 Million
-162,700 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$8.09 - $12.0 $2.14 Million - $3.17 Million
-264,039 Reduced 61.87%
162,700 $1.71 Million
Q1 2021

May 17, 2021

SELL
$10.94 - $15.32 $119,913 - $167,922
-10,961 Reduced 2.5%
426,739 $5.03 Million
Q4 2020

Feb 12, 2021

BUY
$7.84 - $13.4 $3.43 Million - $5.87 Million
437,700 New
437,700 $5.13 Million

Others Institutions Holding FULC

About Fulcrum Therapeutics, Inc.


  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $244M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track This Portfolio

Track Ikarian Capital, LLC Portfolio

Follow Ikarian Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ikarian Capital, LLC with notifications on news.